slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 25,441-25,470
Pages 1,349
Rows per page 30
Beat
25,441-25,470 of 40,452
19
The slide uses a pull-quote from a scientific paper to establish authority.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
20
The slide uses a process flow framework to show the integration of AI at specific stages of therapeutic development.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
21
Uses a Venn diagram to represent the intersection of three properties optimized by AI.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
22
The slide uses a visual comparison between a small sampled space (50k) and a much larger hypothetical sequence space (7 million) to demonstrate the efficiency of the AI approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
23
Case study slide showing correlation metrics (Pearson, Spearman, RMSE) and a histogram comparing predicted affinity to Trastuzumab.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
24
The slide uses a process flow diagram to show AI input leading to improved antibody outcomes.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
25
The slide uses three charts: two line charts showing optimization over generations and one scatter plot showing the distribution of variants.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
26
The slide uses a histogram to visualize the distribution of binding affinity (-log10(KD)) for designed variants compared to the wild-type Trastuzumab baseline.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Visualization1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Competition1 hit
33
The slide includes a section for Management team and Board of Directors with headshots and titles, plus a logo grid at the bottom.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Team1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
11
Pharmacokinetic study results showing extended half-life for the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
13
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
14
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
15
The slide illustrates the escalation of doses for both SAD and MAD study arms.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
16
SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
17
Includes box plots for AUC and Cmax across dose levels (1, 3, 8, 15, 25, 50 mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
18
The diagram illustrates a 4-way cross-over design with 4 patients, each receiving a different sequence of placebo and three dose levels (1mg, 3mg, 8mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
19
The slide presents clinical trial baseline data for a very small sample size (N=4).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
20
The table displays n (%) for adverse events related to the study drug.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
21
Data represents NT1 patients; N=4 per dose; P-values indicate statistical significance vs placebo.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
22
The chart uses a split x-axis to show pre-dose baseline and post-dose results. The 8mg dose maintains maximum sleep latency (40 min) for the duration of the test.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
23
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
24
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
25
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
26
Includes specific line items for share-based compensation, depreciation, amortization, separation expense, tax effects, non-cash interest, and a Janssen arbitration award.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem1 hit